DRD4
DRD4 (dopamine receptor D4) is a G protein-coupled receptor for the catecholamine neurotransmitter dopamine. As a D2-type receptor it couples to G(i)/G(o) proteins and inhibits adenylate cyclase, and it is expressed in the mesolimbic system of the brain. Browse Assay Genie's current range of DRD4 research reagents below, or read on for the biology behind the target.
The DRD4 protein is a G protein-coupled receptor for dopamine, the catecholamine neurotransmitter hormone often described as the brain's reward chemical, linked to motivation, reinforcement learning and pleasure. DRD4 is also activated by epinephrine and norepinephrine, and by numerous synthetic agonists and drugs. Ligand binding causes a conformation change that triggers signalling through guanine nucleotide-binding proteins (G proteins) and modulates downstream effectors such as adenylate cyclase.
Dopamine receptors fall into two categories. DRD4, together with DRD2 and DRD3, is a D2-type receptor coupled to G(i)/G(o) proteins, which mediates inhibition of adenylate cyclase activity. D1-type receptors, DRD1 and DRD5, couple to G(s) proteins and promote adenylate cyclase activation. The two types have antagonistic effects, particularly in the striatum, where they govern voluntary movement and reward. DRD4 is expressed in the mesolimbic system, a brain region that regulates emotion and complex behaviour. It also modulates the circadian rhythm of contrast sensitivity by regulating rhythmic expression of NPAS2 in retinal ganglion cells. The receptor belongs to the G protein-coupled receptor 1 family and is found at the cell membrane.
The DRD4 gene encodes the D4 subtype of the dopamine receptor and is a target for drugs that treat schizophrenia and Parkinson disease. Mutations have been associated with behavioural phenotypes, including autonomic nervous system dysfunction, attention deficit/hyperactivity disorder and the personality trait of novelty seeking. The gene contains a polymorphic number (2-10 copies) of tandem 48 nt repeats, and the reference sequence shows four. Mouse and rat both have a Drd4 ortholog.
DRD4 is a G(i)/G(o)-coupled D2-type receptor that inhibits adenylate cyclase, making it a model for studying dopaminergic signal transduction.
The gene is a drug target in schizophrenia and Parkinson disease, and variants are linked to ADHD and novelty seeking.
DRD4 is expressed in the mesolimbic system, which regulates emotion and complex behaviour, motivation and reinforcement learning.
DRD4 modulates the circadian rhythm of contrast sensitivity by regulating rhythmic NPAS2 expression in retinal ganglion cells.
DRD4 is a G protein-coupled receptor for dopamine, and is also activated by epinephrine and norepinephrine. It couples to G(i)/G(o) proteins and inhibits adenylate cyclase. It is expressed in the mesolimbic system and modulates the circadian rhythm of contrast sensitivity in the retina.
DRD4, DRD2 and DRD3 are D2-type receptors that couple to G(i)/G(o) and inhibit adenylate cyclase. DRD1 and DRD5 are D1-type receptors that couple to G(s) and activate it. The two types act antagonistically, notably in the striatum.
Yes. The gene is a target for drugs treating schizophrenia and Parkinson disease, and mutations are associated with ADHD, autonomic dysfunction and novelty seeking. It carries a polymorphic 2-10 copy 48 nt repeat. Mouse and rat Drd4 orthologs exist; check the datasheet of any product for its validated reactivity.
Other dopamine receptor family members with products at Assay Genie, including fellow D2-type receptors and the D1-type DRD1.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P21917; product specifications from Assay Genie datasheets.